An iron-carboxylate-based metal-organic framework for furosemide loading and release by Devi, Yanita et al.
1 23






J Mater Sci (2020) 55:13785-13798
DOI 10.1007/s10853-020-05009-3
An iron–carboxylate-based metal–organic
framework for Furosemide loading and
release
Yanita Devi, Ignatius Ang, Felycia Edi
Soetaredjo, Shella Permatasari Santoso,
Wenny Irawaty, Maria Yuliana, Artik
Elisa Angkawijaya, et al.
1 23
Your article is protected by copyright and
all rights are held exclusively by Springer
Science+Business Media, LLC, part of
Springer Nature. This e-offprint is for personal
use only and shall not be self-archived in
electronic repositories. If you wish to self-
archive your article, please use the accepted
manuscript version for posting on your own
website. You may further deposit the accepted
manuscript version in any repository,
provided it is only made publicly available 12
months after official publication or later and
provided acknowledgement is given to the
original source of publication and a link is
inserted to the published article on Springer's
website. The link must be accompanied by
the following text: "The final publication is
available at link.springer.com”.
CHEMICAL ROUTES TO MATERIALS
An iron–carboxylate-based metal–organic framework
for Furosemide loading and release
Yanita Devi1, Ignatius Ang1, Felycia Edi Soetaredjo1,2, Shella Permatasari Santoso1,2,* ,
Wenny Irawaty1, Maria Yuliana1, Artik Elisa Angkawijaya3, Sandy Budi Hartono1,
Phuong Lan Tran-Nguyen4, Suryadi Ismadji1,2, and Yi-Hsu Ju2,3,5
1Department of Chemical Engineering, Widya Mandala Surabaya Catholic University, Kalijudan 37, Surabaya 60114, Indonesia
2Department of Chemical Engineering, National Taiwan University of Science and Technology, No. 43, Sec. 4, Keelung Rd.,
Da’an District, Taipei City, Taiwan
3Graduate Institute of Applied Science and Technology, National Taiwan University of Science and Technology, No. 43, Sec. 4,
Keelung Rd., Da’an District, Taipei City, Taiwan
4Department of Mechanical Engineering, Can Tho University, 3-2 Street, Can Tho City, Vietnam
5Taiwan Building Technology Center, National Taiwan University of Science and Technology, No. 43, Sec. 4, Keelung Rd.,
Da’an District, Taipei City, Taiwan
Received: 24 January 2020




Media, LLC, part of Springer
Nature 2020
ABSTRACT
An iron–carboxylate-based metal–organic framework, Fe-MIL100, has been
synthesized using acid-free solvent at room temperature. Fe-MIL100 was pre-
pared by combining Fe/H3BTC/NaOH/H2O (H3BTC = trimesic acid) at a
molar ratio of 1.5:1.0:x:880, where x is the varied NaOH concentration at 1.5, 3.0,
and 5.0 M. The effect of NaOH molar concentration on the formation of Fe-
MIL100 was studied. Characterizations of the Fe-MIL100 were carried out using
powder X-ray diffraction (XRD), scanning electron microscopy (SEM), nitrogen
(N2) adsorption–desorption, and thermogravimetry analysis (TGA). The
obtained Fe-MIL100, with x NaOH of 3.0 M, has an octahedral crystal shape
(a = 73.41 Å), crystal size ranging from 100 to 400 nm, BET surface area of
1,446.4 m2/g, a pore volume of 0.829 cm3/g, and thermal degradation tem-
perature of 358 C. The potential of Fe-MIL100, a drug carrier device, was tested
against Furosemide (a loop diuretic). As studied using the Langmuir adsorption
isotherm model, 392.4 mg of Furosemide can be loaded per g of Fe-MIL100. The
kinetic release of Furosemide was examined at 2 different biological pH of 5.8
and 7.4. The release profile of Furosemide was recorded within 24 h; it was
found that the release profile follows the pseudo-first-order kinetics at pH 5.8
with a percent cumulative release of 41.56% and Korsmeyer–Peppas model at
pH 7.4 with a percent cumulative release of 68.46%. The electrostatic repulsion
drove the release of Furosemide from Fe-MIL100 due to the same negative
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charge of the compounds. Fe-MIL 100 at low concentration (\ 30 lg/mL) shows
good biocompatibility toward the 7F2 normal cell lines.
Introduction
Metal–organic frameworks (MOFs) are porous inor-
ganic particles, they are consisting of networks of
multidentate ligands that hold the metal cluster as
the central building blocks. MOFs have exciting fea-
tures such as high surface area, high and
adjustable porosity, and high crystallinity. Owing to
those features, MOFs have excellent adsorptive and
absorptive capability [1–4]. For instance, the presence
of MOFs in CO2 photoreduction systems can improve
the CO2 adsorption capacity [3]. In the water desali-
nation membrane, the addition of MOFs helps to
improve desalination performance by increasing
adsorption capacity toward solutes [2]. In drug-de-
livery systems, the high adsorption capacity of MOFs
allows high drug loading capacity [5, 6]. In this study,
the utilization of MOF as a drug carrier will be pur-
sued further. Although the use of MOF as a drug
carrier has been widely developed, the opportunity is
still extensive, predominantly the Material of Insti-
tute Lavoisier (MIL) family (specifically Fe-MIL100)
[7].
Fe-MIL100 is an iron–carboxylate MOF which
comprises Fe as the metal center and trimesic acid
(benzene-1,3,5-tricarboxylic acid, abbreviated as
H3BTC) as the ligand linker. Previously, the synthesis
of Fe-MIL100 involves the use of hydrofluoric acid
(HF) or nitric acid (HNO3) solvent, which is harmful
and hazardous. A more sustainable approach in the
synthesis of Fe-MIL100 has been proposed by Guesh
and group, where sodium hydroxide (NaOH) solu-
tion was used as the solvent instead of HF or HNO3
[8]. This sustainable approach has a synergistic effect
on the biocompatibility of Fe-MIL100. The use of Fe-
MIL100 as a drug carrier can give several advantages;
that is, the presence of Fe transition metals is essential
for many biological processes [9], and H3BTC ligand
has been found to be non-toxic and biocompatible
[10], suitable for small or big molecules drug, and
suitable for hydrophilic or hydrophobic drugs.
Low solubility and permeability are the main
obstacles that limit the efficiency of therapeutic
drugs. More than 40% of the New Chemical Entities
(NCEs) have been developed to match the evolution
of diseases that require rapid treatment [11]. How-
ever, most of them inherit similar therapeutic effi-
ciency constraints; a drug-delivery system is needed
to resolve the issue. Furthermore, the proper drug-
delivery system can help to deliver drugs to the
designated target safely. The drug-delivery system is
involving the use of a drug carrier to load and
releasing the drug [12]. A considerable amount of
drug carriers has been developed within the past few
years (e.g., organic compounds and polymers), yet
most of them possess a low loading capacity due to
the limited structural adjustment and poor absorptive
sites [5, 6, 13]. Fe-MIL100 has been reported to be a
potential drug carrier for Aspirin, Isoniazid, Dox-
orubicin, Aceclofenac, and Ibuprofen [14–17]. In this
work, Fe-MIL100 is applied as a drug carrier for
Furosemide. Furosemide is a loop diuretic drug that
uses to treat hypertension and relieves swelling
caused by heart failure, liver disease, and kidney
disease. Similar to other loop diuretics, Furosemide
has low solubility in aqueous solution, that is only
0.18 mg/mL at pH 2.3 and 13.36 mg/mL at pH 10
[18]. Several techniques have been carried out to
optimize the delivery of Furosemide, such as using
co-solvents, pH control, nano-encapsulation, solid
dispersion, complexation with cyclodextrin, micro-
crystalline cellulose, and composite hydrogels
[19–25]. Nevertheless, most of the results are yet
satisfying. Some techniques experience a burst-re-
lease effect that can decrease drug efficiency [26].
Also, there is a possibility of agglomeration with the
use of micronized particles (especially in solid dis-
persion technique), which can result in health com-
plications [27].
To the best of our knowledge, the drug-delivery
system of Furosemide utilizing tunable particle
(i.e., Fe-MIL100) has not been studied. The applica-
bility of Fe-MIL100 as a drug carrier for Furosemide
is being investigated; various mathematical models
were applied for Furosemide loading and release. Fe-
MIL100 was synthesized via a modified (safer) route
as proposed by Guesh et al., where NaOH basic
solution was used as the solvent in the synthesis
instead of acid solvent [8]. It has been noted that the
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presence of NaOH plays an essential role in the
synthesis of Fe-MIL100; however, the influence of
NaOH amount on the formation of Fe-MIL100 is still
unclear. In this work, the effect of NaOH was
examined on the synthesis process and the charac-
teristics of the product.
Materials and methods
Materials
The chemicals used to prepare Fe-MIL100 were iron
(II) sulfate heptahydrate (FeSO4.7H2O, 99%), trimesic
acid, or H3BTC (C9H6O6, 95%), and sodium hydrox-
ide (NaOH, 97%). Ethanol (C2H6O, 99.5%) was used
as the solvent, while sodium chloride (NaCl, 99%),
potassium chloride (KCl, 99%), sodium phosphate
dibasic dihydrate (Na2HPO4.2H2O, 99.5%), sodium
phosphate monobasic monohydrate (NaH2PO4.H2O,
99%), and potassium phosphate monobasic (KH2PO4,
99%) were used to prepare the buffer solutions.
Furosemide (C12H11ClN2O5S, 98%) was chosen as the
drug model for loading and release study. All the
chemicals used in this study were purchased from
Sigma-Aldrich and were directly used without fur-
ther purification.
Synthesis of Fe-MIL100
The synthesis method by Guesh et al. was adopted
for preparing Fe-MIL100 with slight modification [8].
H3BTC (7.6 mmol) was dissolved using NaOH solu-
tion at three different molar concentrations (1.5, 3.0,
and 5.0 M). Meanwhile, FeSO4.7H2O (11.4 mmol)
was dissolved in deionized water; then, it was added
dropwise to the previously prepared H3BTC solution.
The final mixture has a molar ratio of Fe/H3BTC/
NaOH/H2O of 1.5:1:x:880, where x = 1.5, 2.5, 3.0, 4.0,
and 5.0. The synthesis was carried out at room tem-
perature (30 C) under constant stirring conditions
(200 rpm) for 24 h. The resulting solids were sepa-
rated from the solution using Thermo Scientific
Medifuge centrifuge at 3,700 rpm for 15 min. Subse-
quently, the solids were washed using reverse
osmosis water and ethanol for 3–5 times and then
soaked in water for 1 h under constant stirring at
60 C. The resulting products were collected and
placed in a vacuum oven at 80 C for 6 h.
Characterization of Fe-MIL100
The crystallinity pattern of the samples was recorded
using Philips X’pert X-ray Diffractometer with a
copper Ka radiation source (k = 1.5425 Å) at 40 kV
and 30 mA. Subsequently, Rietveld refinement anal-
ysis was conducted on the obtained XRD pattern of
samples using a computer program Match! (version
3.8.3.151 64-bit) [28]. The surface morphology images
were acquired by a JEOL JSM-6500F Field Emission
Scanning Electron Microscopy. The BET surface area
and total pore volume were measured by N2
adsorption–desorption using Quantachrome’s
Quadrasorb SI at - 196 C, and the outgassing pro-
cess was conducted at 200 C for 6 h. Thermal sta-
bility was analyzed using thermal gravimetric
analysis (TGA) in a PerkinElmer TGA 8000, at the
temperature range of 26.7–600 C with a heating rate
of 10 C/min under nitrogen gas flow (20 mL/min).
Adsorption kinetic experiments
Fe-MIL100 was dried overnight at 110 C prior to the
experiment. 70 mg of Furosemide was dissolved in
100 mL ethanol. 20 mg of dried Fe-MIL100 was
introduced to the prepared Furosemide solution. The
adsorption was conducted for 12 h at room temper-
ature in a shaking water bath (Memmert SV-1422).
An aliquot of the solution was taken within a specific
time interval to measure the residual Furosemide
concentration. The residual concentration of Fur-
osemide was measured using a direct UV–Vis spec-
trophotometer measurement at a wavelength of
286 nm, without the addition of reagents.
The amount of Furosemide adsorbed at a specific
time (qt) was calculated using Eq. (1) as follows:
qt ¼
C0  Ctð ÞV
W
ð1Þ
where C0 is the initial concentration of Furosemide,
and Ct is the residual concentration of Furosemide at
a specific time (mg/L). V is the total volume of
solution (L), and w is the amount of Fe-MIL100 (g).
Adsorption isotherm experiments
The adsorption isotherm experiments were carried at
various initial concentrations of Furosemide (25 to
300 mg/L). 20 mg of Fe-MIL100 was introduced into
100 mL of prepared Furosemide solution. Adsorption
was conducted for 12 h at room temperature in a
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water bath shaker. The residual concentration of
Furosemide was measured using a UV–Vis spec-
trophotometer at a wavelength of 286 nm. The equi-
librium amount of Furosemide adsorbed (qe) was
calculated using Eq. (2) as follows:
qe ¼
C0  Ceð ÞV
W
ð2Þ
where Ce is concentrations of Furosemide at equilib-
rium (mg/L).
Loading and release experiments
The loading experiments were carried out by adding
a certain amount of Fe-MIL100 into the Furosemide
solution under stirring for 12 h. Furosemide-loaded
Fe-MIL100 was separated from the solution by cen-
trifugation at 3700 rpm for 15 min. The solid was
washed using reverse osmosis water and ethanol,
and then placed in a vacuum oven at 80 C until dry
for 6 h. Release experiments were carried out using
the dialysis membrane under the stirring condition at
37 C for 12 h in two different phosphate buffer pH
of 5.8 (to simulate large intestine fluid) and 7.4 (to
simulate small intestine fluid).
An aliquot (3 mL) of the solution was taken within
a specific time interval to measure the Furosemide
concentration released. Subsequently, 3 mL of fresh
buffer solution was added to maintain the same
volume of the system. The sample was diluted sev-
eral times before analyzed using Shimadzu UV mini-
1240 Spectrophotometer at 286 nm.
The release of Furosemide from the adsorbent was




where Ct and C0 are the released and initial concen-
trations of Furosemide loaded in Fe-MIL100 (mg/L),
respectively.
Biocompatibility assay
The biocompatibility of the synthesized Fe-MIL 100
was tested against mouse bone marrow cells 7F2.
Different doses of Fe-MIL 100 were introduced to cell
culture, which is 10, 25, 30, 50, 75, 100, and 125 lg/
mL. Cell viability was determined 12, 24, and 48 h
after incubation in media containing Fe-MIL 100. The
detailed culture procedures can be found elsewhere
[29]. After incubation, 20 lL of 5 mg/mL MTT in PBS
was added to the culture and then incubated for 4 h.
The MTT mixed media were then replaced with
0.2 mL DMSO. Cell viability (%) is then calculated as
Eq. (4):
%Cell viability ¼ Absi
Abs0
 100% ð4Þ
where Absi is the absorbance of the cell, and Abs0 is
the absorbance of the blank. The absorbance was
measured at 570 nm using a microplate reader Biotek
PowerWave XS.
Results and discussion
Effect of NaOH in the formation of Fe-
MIL100
Conventionally, Fe-MIL100 is synthesized using
hazardous solvents (i.e., HF or HNO3) via a
solvothermal process which requires high thermal
energy. A sustainable synthesis route for Fe-MIL100
using an amiable solvent (NaOH solution) and low
(room) temperature overcomes the conventional
synthesis method. In the formation of Fe-MIL100,
H3BTC acts as a Fe binding ligand. Prior to the
binding, deprotonation of H3BTC must occur; this
results in the formation of BTC (deprotonated
H3BTC) species, which are negatively charged
ligands that lose 3 H? ions. The difference in charge
between BTC (negative charge) and Fe (positive
charge) encourages the formation of the metal–or-
ganic networks. In conventional synthesis, high
thermal energy is needed to deprotonate both the
ligand and acid (as the complexation modulator).
Meanwhile, in the use of NaOH solvent, the basicity
of NaOH facilitates the ligand deprotonation without
the need of high thermal energy [30]. NaOH played
an essential modulatory role in the synthesis of Fe-
MIL100 under the basic condition and low tempera-
ture. A suitable amount of NaOH results in the
favorable formation of Fe-MIL100; partial deproto-
nation might occur if the amount of NaOH is too
small, and the formation of metal hydroxide species
can arise if the amount of NaOH is excessive [31–33].
Thus, it is crucial to evaluate the effect of the amount
of NaOH on the formation of Fe-MIL100.
NaOH acts as a deprotonating agent for H3BTC by
substituting the H? ions with Na? ions, thus forming
Na3BTC. The deprotonation of H3BTC occurs when
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the pH of the solution exceeds the acid dissociation
constant (pKa) [4], where The pKa values of the
H3BTC in a sequence are 3.12, 3.89, and 4.70. Fur-
thermore, the deprotonation of H3BTC can increase
the solubility of the compound. As NaOH was added
dropwise, the insoluble H3BTC solution (with white
solid particles observed) starts to dissolve, and
eventually, crystal clear solution was obtained
(Fig. 1a). Next, Fe solution was added to the dis-
solved ligand solution. A decrease in final solution
pH was observed after metal addition (Fig. 1b); this is
since metal is a Lewis acid. The highest Fe-MIL100
yield is obtained from the mixture with a final pH of
5.8, which is the Fe-MIL100 synthesized with NaOH
at x = 3.0.
The amount of NaOH added is affected by the
yield of Fe-MIL100 (Fig. 1b). Fe-MIL100, which syn-
thesized with NaOH at x = 1.5, gives the lowest yield
(36.60%). The %yield obtained from the other varia-
tion, x = 3.0 and 5.0, were 66.00% and 55.61%,
respectively. The low yield of Fe-MIL100 at x = 1.5 is
because there is not enough NaOH to deprotonate
and dissolve the linker fully; this was visually indi-
cated by the appearance of white solids (insoluble
organic ligand) shortly after the metal solution is
added. The unreacted ligand was then washed using
water/ethanol to remove it. A similar phenomenon
was observed during Fe-MIL100 synthesis using
NaOH at x = 2.5. Full linker deprotonation (complete
dissolution) was obtained using NaOH at x = 3.0,
and 5.0. Even though NaOH at x = 5.0 was capable of
dissolving the mixture completely, it was found that
the presence of excess NaOH may promote the for-
mation Fe(OH)3 as a by-product [34].
The %yield (Fig. 1b) shows that NaOH at x = 1.5
gives the lowest yield, followed by x = 5.0. NaOH at
x = 2.5 and 4.0 gives an intermediate yield, while at
x = 3.0 is the highest. In the subsequent characteri-
zation study, MIL-100 (Fe) produced using x = 1.5,
3.0, and 5.0 will be further evaluated because the
three samples provide the most remarkable yield
differences, whereas MIL-100 (Fe) with NaOH at
x = 2.5 and 4.0 are not used.
Characterization of MIL-100(Fe)
Powder XRD patterns of the synthesized Fe-MIL100
samples were observed to evaluate the influence of
NaOH. As shown from the XRD results in Fig. 2, Fe-
MIL100 synthesized at a different molar ratio of
Figure 1 a Schematic diagram illustrating the physical appearance change of Fe and H3BTC mixture due to the addition of NaOH, in the
synthesis of MIL-100(Fe). b The curve showing the effect of NaOH molar ratio on the formation of Fe-MIL100.
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NaOH (x = 1.5, 3.0, and 5.0) exhibits quite similar
patterns. A Rietveld refinement was conducted to
match the XRD pattern of the samples against Fe-
MIL100 from the database, and the matching results
were given in Supplementary Data Figure S1–S3. The
goodness of fit of the Rietveld refinement is pre-
sented in Table S1. It is noted that Fe-MIL100 x = 1.5
and x = 3.0 have lower Bragg R-factor and Chi-
square (v2), and this indicates that the observed and
calculated patterns can converge well. However, Fe-
MIL100, with x = 3.0, shows a better correlation,
which is indicated by the higher peak matching with
the selected phase from the database (Table S1). The
synthesized Fe-MIL100, with x = 3.0, has a better
pattern match to the reference database. Fe-MIL100,
x = 5.0, exhibits different patterns from the reported
one, precisely the appearance of peaks detected in the
2h range of 19.95 to 21.23 degrees. The synthesized
Fe-MIL100, x = 3.0, has the highest product yield and
shows remarkable peak similarities to the XRD pat-
tern of the literature. Furthermore, the calculated unit
cell (a) for the Fe-MIL100, x = 3.0, is 73.41 Å which is
in a good accordance with the a of the reference
(a = 73.34 Å) [35, 36]. The difference in the XRD
profile between conventional and synthesized (in this
study) Fe-MIL 100 could be due to differences in the
solvent used. NaOH solution used in the synthesis of
Fe-MIL 100 initiates the formation of metal hydrox-
ide, which affects the XRD pattern, whereas the for-
mation of metal hydroxide does not occur in the
conventional Fe-MIL 100 which prepared using HF
solvent [8].
The as-synthesized Fe-MIL100, x = 3.0, has octa-
hedral shaped particles with a crystal size ranging
from 100 to 400 nm (Fig. 3b), which is similar to the
reported literature [8, 15, 36, 37]. The non-homoge-
neous crystal size and shape of the obtained Fe-
MIL100 are acceptable, considering that the synthesis
process was conducted at room temperature (not-
thermostatted) and without strict control of sudden
stirring acceleration. In the case of high homogeneity,
Fe-MIL100 particles are desirable, and the synthesis
must be conducted at an elevated temperature where
better nucleation and crystal growth occur [38]. Fe-
MIL 100, x = 1.5, shows smaller particle sizes and
more irregular shapes (Fig. 3a), which could be due
to structural collapse. Similarly, for Fe-MIL 100,
x = 5.0, irregular particle shapes were also observed
(Fig. 3c), which could be related to the presence of
metal hydroxide particles.
Based on the N2 adsorption–desorption isotherm
(Fig. 4), the synthesized Fe-MIL100 shows a steep
increase at low relative pressure (P.P0
-1\ 0.2), which
demonstrates the presence of micropore structures
[39]. Brunauer–Emmett–Teller (BET) surface area and
total pore volume of Fe-MIL100 were determined
from the N2 isotherm data by utilizing the following












where P is the partial vapor pressure of adsorbate gas
in equilibrium (Pa), P0 is the saturated vapor pressure
of adsorbate gas (Pa), C is the dimensionless constant,
Va is the volume of gas adsorbed onto the adsorbent
at STP (cm3/g), and VM is the volume of gas adsor-






where SBET is the BET surface area (m
2/g), Na is the
Avogadro’s number, Am is the cross-sectional area of
Figure 2 XRD patterns of the synthesized Fe-MIL100 at various
molar ratios of NaOH, reported Fe-MIL100, and Fe(OH)3. The
asterisks indicate the peaks that belong to the Fe-MIL100;
asterisks indicate the peaks that belong to the iron hydroxide. *
The XRD of Fe-MIL 100 based on published literature [36].
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the adsorbate (m2), and Vm is the molar volume
(cm3). The calculation of the total pore volume (TPV)





where Vsat is the volume of N2 adsorbed into the
adsorbent at saturation (cm3/g), qvap is the density of
N2 at STP (g L
-1), and qliq is the density of liquid N2
at boiling point (g/L). BET surface area and total pore
volume of Fe-MIL100, x = 3.0, are found to be 1446.4
m2/g and 0.829 cm3/g, respectively. The BET surface
area of Fe-MIL100 at x = 1.5 and 5.0 is found to be
1354.6 and 1052.9 m2/g, respectively; the total pore
volume of the corresponding materials is 0.827 and
0.831 cm3/g. Meanwhile, the reported Fe-MIL100
exhibits a BET surface area and total pore volume of
1604.8 m2/g and 0.67 cm3/g, respectively [29, 39].
The obtained BET parameters are quite different from
that of reported literature (Fe-MIL100 produced
using the conventional method), which may be due
to the differences in the synthesis method and solvent
used [8, 15, 36, 37]. The pore size distribution curve
(inset Fig. 4) of the synthesized Fe-MIL100 (x = 3.0)
shows two peaks centered at 2.07 and 2.49 nm,
indicating the occurrence of mesoporous cages which
is the main characteristic of Fe-MIL100. The meso-
porous cages were also observed for Fe-MIL100
synthesized with NaOH at x = 5.0, but not for Fe-
MIL100 with NaOH at x = 1.5. Considering that Fe-
MIL100, x = 3.0, has the highest product yield and
good similarity in characteristics (based on XRD and
N2 sorption) with reference material, this sample is
further investigated.
TGA curve (Fig. 5) shows that Fe-MIL100, x = 3.0,
has excellent thermal stability, where thermal
degradation is starting to occur after 358 C (15.9%
weight loss). Three stages of thermal degradation
were observed for Fe-MIL100, x = 3.0, which is at
Figure 3 SEM image of synthesized Fe-MIL100 at various molar ratios of NaOH.
Figure 4 N2 adsorption–desorption isotherm of Fe-MIL100 with
NaOH at x = 3.0. The inset figure shows the pore size distribution
of Fe-MIL 100.
Figure 5 Thermal gravimetric analysis (TGA) curve of
synthesized Fe-MIL100, x = 3.0.
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46.2–151 C, 151– 358 C, and 358–454 C. The first
stage, with a weight loss of 9.2%, is attributed to the
evaporation of water and volatile guest molecules
(i.e., ethanol). The second stage, a weight loss of 6.7%,
is attributed to the dehydration of water coordinated
with the iron trimers. Finally, significant weight loss
(52.2% by weight) in the range of 358–454 C is
related to the decomposition of the organic linker in
Fe-MIL100. The decomposition of this stage also
marks the breakdown of coordination between met-
als and the linker, which then causes structural col-
lapse and leaves metal oxide as the final residue.
Adsorption kinetic
Comprehensive details about the adsorption of Fur-
osemide on Fe-MIL100 can be evaluated through the
adsorption kinetic results. The pseudo-first- and
pseudo-second-order models were used to correlate
the kinetic data. The nonlinear form of pseudo-first-
and pseudo-second-order is shown in Eqs. (8) and
(9), respectively:
qt ¼ qeð1  ek1tÞ ð8Þ
where t is the adsorption time (h), and k1 is the






where k2 is the pseudo-second-order rate constant
(g/mg h). A fitting using nonlinear regression was
used to determine the pseudo-first- and pseudo-sec-
ond-order parameters [40].
The nonlinear plot in Fig. 6 shows that the
adsorption of Furosemide using Fe-MIL100 occurs
rapidly at the first 6 h adsorption time and gradually
slower over time. The rapid adsorption during the
beginning is due to the high availability of vacant
sites of adsorbent [41, 42]. Meanwhile, as adsorption
proceeded, the availability of vacant sites decreases
as more Furosemides are adsorbed, which further
leads to an equilibrium state [42]. The sum squared
error (R2) in Table 1 shows that pseudo-first-order is
favorably over pseudo-second-order to represent the
kinetic adsorption of Furosemide on Fe-MIL100.
Furthermore, the experimented qe value is also closer
to the fitting qe value of pseudo-first-order than
pseudo-second-order. Better fitting to pseudo-sec-
ond-order suggests that chemisorption is the rate-
controlling step in this process.
Adsorption isotherm
The adsorption isotherm is studied to understand the
adsorption phenomenon and mechanism. Langmuir
and Freundlich isotherm models are used to repre-
sent Furosemide adsorption isotherm on Fe-MIL100.
The Langmuir equation applies to the adsorption on
completely uniform surfaces, regardless of the inter-
action between adsorbed molecules. The Langmuir





where qmax is the theoretical maximum amount of
Furosemide adsorbed into the adsorbent (mg/g)
often called as the adsorption capacity of the adsor-
bent, kL is the Langmuir constant (L/mg), and Ce is
the concentration of the remaining Furosemide in
solution at equilibrium (mg/L) [43]. The Freundlich
adsorption isotherm is an equation model for
heterogeneous adsorbent, and the equation is
expressed as follows:
qe ¼ kFCe1=n ð11Þ
where kF is the Freundlich constant (mg/g) (L/mg)
1/
n, and n is related to the adsorption intensity [43].
The experimental data fitting to both isotherm
models is given in Fig. 7, and all the parameters from
the model are summarized in Table 2. Based on R2
value, it was obtained that the Langmuir model is
more suitable for describing the adsorption of Fur-
osemide on Fe-MIL100. This indicates that
t (h)
















Figure 6 Adsorption kinetics of Furosemide using Fe-MIL100,
x = 3.0, plotted to pseudo-first- and pseudo-second-order.
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Furosemide adsorbed by forming a monolayer on
homogeneous adsorption sites of Fe-MIL100. The
Langmuir constant shows a relatively low value (kL-
= 0.067 L/mg), which indicates that the affinity
between Fe-MIL100 as adsorbent and Furosemide is
small [41].
Loading and release of Furosemide
Furosemide was loaded on Fe-MIL100 using ethanol
as a solvent; this is since Furosemide is highly soluble
in ethanol compared to other solvents. For instance,
the solubility of Furosemide in the water at 30 C is
25.32 mg/L, while its solubility in ethanol
is[ 2.25 9 103 mg/L [44]. Generally, drugs with low
solubility in aqueous solutions tend to have a high
affinity with the hydrophobic pores of the MIL family
[7]. Based on batch adsorption experiments, the
amount of Furosemide loaded on Fe-MIL100 is
0.2697 mg of Furosemide per mg of Fe-MIL100, and
the loading efficiency is 67.55%.
In vitro release of Furosemide was studied in two
different pHs of phosphate buffer solutions, that are
5.8 and 7.4, respectively. The release of Furosemide
(at the stated pHs) is driven by the electrostatic
repulsion between negative charged Furosemide and
Fe-MIL100. Furosemide is a weak acid with a pKa
value of 3.8; thus, the release of Furosemide at a pH
of 5.8 and 7.4 will cause deprotonation of the car-
boxyl cluster since pH solution[pKa [45]. Similarly,
at pH 5.8 and 7.4, Fe-MIL100 exhibits negative sur-
face charges due to partial deprotonation of carboxyl
cluster in carboxylic acid of the outer surface of the
particle [37, 46].
According to the release profile, as shown in
Fig. 8a, there are two stages of Furosemide release
from Fe-MIL100. For the profile release at pH 5.8—
the first stage is a rapid release, up to 35.31% cumu-
lative release, observed within the initial 8 h which is
attributed to the release of drug located in the pore
near to the outer surface of particle, and an adequate
solubility of the drug in pH 5.8 (C 270 mg/L at
37 C) [18]. The second stage is a slow release, up to
41.56% cumulative release, observed within the next
16 h, which indicate the release of drug located
within the pores. The slower release is due to the fact
that there are only a few Furosemide molecules
available so that the repulsion forces weaken. For the
profile release at pH 7.4—as shown in Fig. 8b, there is
a distinct release profile at pH 7.4 compared to pH
Table 1 Calculated adsorption kinetic parameters of Furosemide on Fe-MIL100, x = 3.0
Initial concentration (mg L-1) qe, exp (mg g
-1) Pseudo-first-order Pseudo-second-order
qe1, cal (mg g
-1) k1 (h
-1) R2 qe2, cal (mg g
-1) k2 (g mg
-1 h-1) R2
70 269.7 286.6 0.279 0.995 377.3 0.001
0.988
Adsorption condition: T = 30 C, C0 = 20 mg
Ce (mg/L)















Figure 7 Adsorption isotherm of Furosemide using Fe-MIL100,
x = 3.0, plotted to Langmuir and Freundlich equations.
Table 2 Calculated
adsorption isotherm
parameters of Furosemide on
MIL-100(Fe), x = 3.0
Langmuir isotherm Freundlich isotherm
qmax (mg g
-1) kL (L mg
-1) R2 kF (mg g
-1) (L mg-1)1/n n R2
392.4 0.067 0.995 112.5 4.364 0.954
Adsorption condition: T = 30 C, C0 = 20 mg
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5.8. At pH 7.4, and the release of Furosemide from Fe-
MIL100 keeps rising during 24 h observation, with a
cumulative release of 68.46%. This is due to the high
solubility of the drug in more alkaline pH
(C 1.9 9 103 mg/L, at 37 C), and higher repulsion
forces between the more negative charged Fur-
osemide and Fe-MIL100 [18].
With a loading efficiency of 67.55%, the cumulative
release of Furosemide using Fe-MIL100 was found to
be 41.56% (at pH 5.8) and 68.46% (at pH 7.4). These
results indicate that Fe-MIL100 has good potential in
increasing the bioavailability of Furosemide. In a
previous study, by using a matrix tablet made from
polypropylene powder, the release of Furosemide
only reached 37.9% (with initial loading efficiency of
73.8%) [47]. The cumulative release efficiency of
Furosemide obtained in this study is also comparable
to the cumulative release of other drugs loaded in Fe-
MIL100. For instance, the cumulative release of Iso-
niazid loaded on Fe-MIL100 after 24 h is 50.4% (at pH
5.8) and 72.2% (at pH 7.4) [15]. Cumulative release of
Doxorubicin on polypyrrole-modified Fe-MIL100 is
42.7% (at pH 7.4) and 82.7 (at pH 5.0) [17].
Several kinetic models were applied to achieve
particular elucidation regarding the release behaviors
of Furosemide from Fe-MIL100. The models used are
zero-order kinetic, first-order kinetic, Korsmeyer–
Peppas, and Higuchi. The mathematical forms of the
kinetic models are as follows:
R ¼ Re þ k0t ð12Þ
where R and Re are the cumulative release percentage
of Furosemide at specific and equilibrium time (%),
respectively. k0 is the zero-order release constant
(h-1).
R ¼ Re 1  ek1t
 
ð13Þ





where MtM1 equals to the amount of Furosemide
released at specific and equilibrium time (%),
respectively. kM is the dimensionless Korsmeyer–





where kH is the dimensionless Higuchi constant [29].
The calculated parameters obtained from fitting of
the experimental data are given in Table 3. The
release of Furosemide from Fe-MIL100 in PBS, at pH
5.8, fits the first-order kinetic model better than other
models, with a high correlation coefficient value of
0.989. This indicates that the drug dissolution rate is
affected by the amount of drug loaded into the par-
ticle [50]. Meanwhile, the release in PBS at pH 7.4 fits
the Korsmeyer–Peppas model, with a correlation
coefficient value of 0.991. The n value of 0.45 shows
that the release of Furosemide from Fe-MIL100 fol-
lows the Fickian diffusion with a cylindrical geome-
try [51].
The stability of Fe-MIL100 was observed through
the loss of Fe content in the matrix. The tests were
conducted by soaking a known amount of Fe-MIL100
into PBS solution at pH 5.8 and 7.4, for 24 h; the Fe
t (h)
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Figure 8 Release kinetic models of Furosemide from Fe-MIL100, x = 3.0, at a pH 5.8 b pH 7.4.
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content was measured using ICP-AES. At pH 5.8,
1.91% of Fe is lost, while at pH 7.4, 4.37% of Fe is lost.
This indicates the degradation of the matrix that
occurs when Fe-MIL100 is in PBS; thus, the rapid
release of Furosemide from Fe-MIL100 can be
attributed to the partial matrix degradation of Fe-
MIL100 in phosphate-containing solution. As studied
by Bellido et al. (2014), the presence of phosphate ion
from a PBS solution causes structural degradation of
MIL-100(Fe) [46]. This is since phosphate ion of PBS is
able to form coordination bonds with the Lewis metal
centers, which cause the detach of metal from the
carboxylate linker of H3BTC [35, 52]. The more sig-
nificant loss at pH 7.4 is due to more phosphate ions
from PBS to form a coordination bond with the Lewis
metal centers, which further leads to the gradual
replacement of the carboxylate linker [35, 52].
Biocompatibility assay
The in vitro biocompatibility assay of synthesized Fe-
MIL 100 (NaOH at x = 3.0) was evaluated against the
7F2 cell line, and the result is presented as cell via-
bility (Fig. 9). Fe-MIL 100 with a low dose of 10 lg/
mL shows good biocompatibility toward the cell even
after 24 h incubation, with cell viability 95.4%.
However, prolonged incubation time causes the cell
viability reduced to 89.8%. Good biocompatibility,
with cell viability[ 80%, can be maintained up to
30 lg/mL Fe-MIL 100 dose and 12 h incubation time.
Fe-MIL 100 at higher doses and prolonged incubation
times is potentially toxic to cells, which is indicated
by cell viability below 80%. The cytotoxicity of Fe-
MIL 100 can be caused by the presence of metal,
which triggers the formation of reactive oxygen spe-
cies that cause damage to cells [15].
Conclusion
The alkali-modified Fe-MIL100 was synthesized at
room temperature (30 C) using NaOH solution as
the solvent, instead of the hazardous HF and HNO3.
The highest yield of Fe-MIL100 of 66.00% was able to
achieve from synthesis using NaOH at a molar ratio
x = 3.0. The coordination of metal-linker, in the for-
mation of Fe-MIL100, was driven by the deprotona-
tion of the H3BTC linker in the presence of ions from
NaOH. The as-synthesized Fe-MIL100 exhibits a
length of the unit cell edge and BET surface area of
73.41 Å and 1,446.4 m2/g, respectively. Fe-MIL100
can be an excellent material for Furosemide adsorp-
tion, which represented well by the pseudo-first-
order model (kinetically) and Langmuir model
(isothermally). An amount of 0.2697 mg of Fur-
osemide can be loaded per mg of Fe-MIL100, with a
loading efficiency of 67.55%. The release profile of
Furosemide from Fe-MIL100 was studied in PBS
solution at two different biological pH of 5.8 and 7.4.
The release of Furosemide from Fe-MIL100 in PBS at
pH 5.8 and 7.4 fitted well with the first-order kinetic
(R2 = 0.989) and Korsmeyer–Peppas model
(R2 = 0.991), respectively. Meanwhile, the percent
Table 3 Calculated release kinetic parameters of Furosemide
from Fe-MIL100, x = 3.0

















Figure 9 Cell viability assay of Fe-MIL 100 (NaOH at x = 3.0)
against mouse bone marrow cells 7F2, at the different dosage and
incubation time.
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cumulative release (within 24 h) in PBS at pH 5.8 and
7.4 was found to be 41.56% and 68.46%, respectively.
At low concentrations, Fe-MIL100 is found to be non-
toxic to normal cells.
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